Fact-checked by Grok 2 weeks ago

Neurofibroma

A neurofibroma is a benign tumor originating from the peripheral nerve sheath, typically manifesting as a soft, skin-colored or flesh-toned bump on or under the skin, formed by an overgrowth of Schwann cells, fibroblasts, and other supportive nerve tissues.^[1]^[2] These tumors can develop along any peripheral nerve in the body and are classified into three main types: cutaneous (superficial skin lesions), subcutaneous (deeper under the skin), and plexiform (involving multiple nerve branches, often resembling a "bag of worms" on imaging).^[3]^[2] While most neurofibromas are noncancerous and asymptomatic, they may cause pain, itching, numbness, or weakness if they compress nearby nerves or structures.^[1]^[3] The primary cause of neurofibromas is mutations in the NF1 gene on chromosome 17q11.2, which encodes neurofibromin, a tumor suppressor protein that regulates cell growth; loss of this function leads to uncontrolled proliferation of nerve sheath cells.^[2] Approximately 90% of cases occur sporadically without a family history, while the remaining 10% are associated with neurofibromatosis type 1 (NF1), an autosomal dominant genetic disorder affecting about 1 in 3,000 people worldwide.^[2]^[3] In NF1 patients, multiple neurofibromas often develop during adolescence or early adulthood, increasing in number and size over time, whereas sporadic cases typically involve solitary lesions appearing between ages 20 and 40.^[1]^[2] Risk factors are limited primarily to having NF1, with no significant differences by sex, race, or ethnicity.^[2] Diagnosis usually begins with a physical examination to identify characteristic soft, dome-shaped nodules less than 2 cm in diameter, followed by imaging such as MRI or CT scans to evaluate deeper or plexiform tumors, and biopsy for confirmation if malignancy is suspected.^[3]^[2] Treatment is often unnecessary for small, asymptomatic lesions, which are monitored periodically; however, surgical excision is recommended for symptomatic, cosmetically concerning, or rapidly growing tumors, with complete removal minimizing recurrence risk.^[1]^[2] In NF1-associated plexiform neurofibromas, approved targeted therapies such as MEK inhibitors (e.g., selumetinib, FDA-approved in 2020 and expanded in 2025) may be used to slow growth, though surgery remains challenging due to their diffuse nature.^[3]^[4] Complications are rare but include malignant transformation in about 10% of NF1-related cases, potential nerve damage from tumor pressure, or scarring from surgical intervention.^[2] Overall, the prognosis is excellent for sporadic neurofibromas, which rarely recur after excision, though NF1 patients require lifelong monitoring for new lesions and associated complications.^[3]^[2]

Overview

Definition and Characteristics

A neurofibroma is a benign peripheral nerve sheath tumor that arises from a mixture of Schwann cells, fibroblasts, and perineural cells within the nerve sheath, resulting in soft, fleshy growths that are typically non-cancerous.^[2]^[5] These tumors form unencapsulated lesions with intermixed cellular components, including nerve fibers, distinguishing them from other nerve sheath tumors.^[6] They often present as skin-colored papules or small subcutaneous nodules and are commonly located on the skin or along peripheral nerves.^[2] Key characteristics of neurofibromas include their slow growth rate and generally painless nature, though they can cause discomfort if they compress nearby structures.^[7] They may occur as solitary lesions in sporadic cases or as multiple tumors, frequently associated with neurofibromatosis type 1 (NF1).^[2] Cutaneous neurofibromas, the most common subtype, typically measure 1-2 cm in diameter, appearing as dome-shaped or pedunculated masses.^[8] Neurofibromas differ from schwannomas, which originate purely from Schwann cells and are encapsulated with a distinct Antoni A and B pattern on histology, whereas neurofibromas lack encapsulation and show a more heterogeneous cell population.^[9] In contrast to malignant peripheral nerve sheath tumors (MPNSTs), which represent an aggressive transformation with rapid growth, invasion, and metastatic potential often arising from preexisting neurofibromas in NF1 patients, neurofibromas remain benign in the vast majority of cases.^[10]^[9] The condition was first described in 1882 by Friedrich Daniel von Recklinghausen as part of the syndrome now known as neurofibromatosis type 1, highlighting the tumors' role in this genetic disorder.^[11]

Epidemiology

Approximately 90% of neurofibromas occur sporadically as solitary lesions without association with neurofibromatosis type 1 (NF1), while the remaining cases are linked to NF1, a genetic disorder with an incidence of approximately 1 in 2,500 to 3,000 live births, though the actual frequency may be higher due to underdiagnosis.^[2]^[12]^[13] Solitary neurofibromas, which arise sporadically without NF1, have an estimated annual incidence of 1 to 2 per 100,000 individuals.^[14]^[15] NF1-associated neurofibromas affect up to 95% of individuals with the disorder by adulthood, particularly cutaneous types that emerge in late childhood or adolescence.^[16] NF1 itself has a population prevalence of about 1 in 3,000, occurring equally across all ethnic groups with no known variations in frequency.^[17] The condition follows an autosomal dominant inheritance pattern, with approximately 50% of cases resulting from de novo mutations in the NF1 gene.^[18] Demographically, NF1-associated neurofibromas show no strong sex bias, impacting males and females equally, though plexiform neurofibromas—a subtype affecting up to 50% of NF1 patients—tend to manifest earlier, often in childhood or even congenitally.^[2]^[19] Onset of cutaneous neurofibromas in NF1 typically occurs during adolescence, with progression throughout life.^[20] The primary risk factor for neurofibromas is a germline NF1 gene mutation, which confers near-certain development in carriers, while sporadic cases stem from somatic mutations without underlying NF1.^[2] As the main genetic driver of NF1-associated neurofibromas, these mutations underscore the disorder's role in tumor predisposition.^[18]

Types

Cutaneous Neurofibromas

Cutaneous neurofibromas are benign tumors that arise from small peripheral nerves within the dermis of the skin. They are characterized histologically by a heterogeneous composition, including Schwann cells, fibroblasts, perineural cells, and mast cells embedded in a myxoid matrix, reflecting their origin from the nerve sheath. These tumors typically present as soft, dome-shaped or pedunculated nodules that are skin-colored or slightly pigmented, measuring a few millimeters to centimeters in diameter. They are freely movable under the skin and generally non-tender, though they may become symptomatic if irritated or traumatized.^[2]^[21]^[22] In patients with neurofibromatosis type 1 (NF1), cutaneous neurofibromas usually begin to appear after puberty, with an average age of onset around 15 years, though they can emerge as early as childhood in some cases. The number of these lesions increases progressively with age, often reaching hundreds or even thousands by adulthood, and they are linked to biallelic inactivation of the NF1 gene in Schwann cell precursors. By age 20, nearly all individuals with NF1 develop these tumors, affecting over 95% of adult patients overall. While solitary cutaneous neurofibromas can occur sporadically in the general population without NF1, multiple lesions are a hallmark feature strongly associated with the condition.^[18]^[23]^[24] The primary clinical concern with cutaneous neurofibromas is cosmetic disfigurement, which can significantly impact quality of life due to their visible and widespread distribution across the body. These tumors are rarely painful unless bumped or during rapid growth phases, such as in pregnancy, and they do not typically cause functional impairment. Management often focuses on surgical excision for symptomatic or aesthetically bothersome lesions, though recurrence is uncommon after complete removal.^[25]^[21]^[2]

Subcutaneous and Nodular Neurofibromas

Subcutaneous neurofibromas are benign tumors arising from peripheral nerves and located within the subcutaneous fat layer or along medium-sized nerves, distinguishing them from more superficial cutaneous variants. While multiple subcutaneous neurofibromas are characteristic of NF1, solitary lesions can occur sporadically in the general population.^[2] These lesions are typically firmer in texture compared to cutaneous neurofibromas and often fixed to the underlying tissue, potentially leading to localized nerve compression that manifests as tenderness or pain.^[18] Nodular neurofibromas, a subtype of subcutaneous neurofibromas, present as discrete nodules clustered along nerve plexuses without diffuse infiltration, measuring less than 2 cm in diameter and exhibiting a characteristic "buttonhole sign" upon palpation where the nodule retracts into the subcutis.^[5] The age of onset for both subcutaneous and nodular neurofibromas is generally during adolescence or early adulthood, though they are uncommon before puberty and become more prevalent with age.^[26] Unlike the hundreds or thousands of cutaneous neurofibromas that may develop in individuals with neurofibromatosis type 1 (NF1), subcutaneous and nodular types occur in fewer numbers, typically in the tens.^[18] Clinically, these neurofibromas present as subtle swellings or palpable nodules beneath the skin, often detectable only by touch rather than visual inspection, and may be associated with mild pain due to nerve involvement.^[22] In patients with NF1, subcutaneous neurofibromas are identified in approximately 15% of adults upon clinical examination, while MRI detects them at a higher rate of 30-40%.^[18] They comprise 10-20% of all neurofibromas in NF1, with biopsy occasionally used for confirmation when malignancy is suspected.^[18]

Plexiform Neurofibromas

Plexiform neurofibromas are benign, infiltrative tumors arising from the nerve sheath, characterized by their diffuse, multinodular growth along nerve plexuses such as the brachial or cervical regions. These tumors typically exhibit a soft, irregular texture often described as a "bag of worms" upon palpation, due to their lobulated and rope-like appearance involving multiple nerve branches, overlying skin, and deeper tissues. Unlike localized neurofibromas, plexiform variants extensively intermingle with neural elements, making them pathognomonic for neurofibromatosis type 1 (NF1) and challenging to delineate anatomically.^[18]^[27] They are present in 20-50% of individuals with NF1, with higher detection rates (up to 50%) via imaging compared to clinical examination. Onset occurs congenitally or in early childhood, typically between birth and age 5 years, and these tumors grow disproportionately to body size during development. Growth is most active in infancy and childhood, often stabilizing in adulthood, though they can enlarge rapidly during periods of hormonal change such as puberty or pregnancy.^[18]^[28] Clinically, plexiform neurofibromas often manifest as visible or palpable masses causing cosmetic disfigurement through soft tissue overgrowth or sagging deformities. They frequently lead to functional impairments, such as scoliosis from spinal nerve root involvement or neurological deficits due to compression of adjacent structures. Patients face an elevated risk of chronic pain and motor or sensory losses, particularly with deep-seated lesions affecting major plexuses. These tumors also carry a higher potential for malignant transformation than other neurofibroma types, though this risk is addressed elsewhere.^[18]^[27]^[28]

Pathophysiology

Genetic Causes

Neurofibromas are primarily associated with mutations in the NF1 gene, located on chromosome 17q11.2, which spans approximately 280 kb and consists of 57 constitutive exons plus four conditionally expressed ones.^[29] This gene encodes neurofibromin, a large cytoplasmic protein (approximately 2,800 amino acids) that functions as a tumor suppressor by negatively regulating the RAS-MAPK signaling pathway through its GTPase-activating protein (GAP)-related domain.^[30] Loss of neurofibromin activity leads to uncontrolled cell proliferation, a hallmark of neurofibroma development.^[31] In neurofibromatosis type 1 (NF1), which underlies most neurofibromas, disease-causing NF1 mutations are typically inactivating and include nonsense, frameshift, splice-site alterations, and large deletions that result in truncated or absent neurofibromin protein.^[32] These mutations follow an autosomal dominant inheritance pattern with nearly 100% penetrance; each child of an affected individual has a 50% risk of inheriting the variant.^[18] Approximately half of NF1 cases arise from de novo (spontaneous) germline mutations, with the remainder inherited from an affected parent.^[18] In tumor formation, biallelic inactivation occurs via a "second hit" somatic mutation in the wild-type NF1 allele within susceptible cells, such as Schwann cells or their precursors, leading to complete loss of neurofibromin function.^[33] Sporadic neurofibromas, which occur in individuals without NF1, require two independent somatic "hits" in the NF1 gene within the same cell lineage to achieve biallelic inactivation, without a predisposing germline mutation.^[34] These tumors are less common than those in NF1 patients and often present as solitary lesions.^[35] While NF1 mutations are the primary genetic driver of benign neurofibromas, rare alterations in other genes, such as SUZ12 or components of the polycomb repressive complex 2 (PRC2), play a role in the progression of some plexiform neurofibromas to malignant peripheral nerve sheath tumors (MPNSTs) but are not implicated in the initial formation of benign lesions.^[36]

Cellular and Molecular Mechanisms

Neurofibromas primarily originate from Schwann cells within the peripheral nerve sheath, where haploinsufficiency of the NF1 gene in these cells initiates tumorigenesis through interactions with the surrounding microenvironment.^[37] Biallelic inactivation of NF1 in the Schwann cell lineage is essential for tumor formation, following the two-hit hypothesis adapted from Knudson's model for tumor suppressor genes, in which the germline mutation provides the first hit and a somatic mutation delivers the second.^[38] This process involves Schwann cells losing both functional NF1 alleles, leading to abnormal proliferation and recruitment of non-neoplastic cells such as fibroblasts and mast cells, which contribute to the tumor's heterogeneous composition.^[39] At the molecular level, loss of neurofibromin—the protein encoded by NF1—results in unchecked activation of the RAS-MAPK/ERK signaling pathway, as neurofibromin normally functions as a GTPase-activating protein (GAP) to hydrolyze active RAS-GTP to inactive RAS-GDP.^[40] This hyperactivation promotes cell proliferation and survival in Schwann cells and other tumor components.^[41] Additionally, NF1 deficiency engages the PI3K/AKT and mTOR pathways, which enhance cellular growth and metabolism; for instance, RAS-mediated PI3K activation leads to AKT phosphorylation and subsequent mTOR signaling, further driving neurofibroma expansion.^[42] The tumor microenvironment plays a critical role in sustaining neurofibroma growth, with haploinsufficient Schwann cells recruiting mast cells and promoting angiogenesis to support tumor survival and progression.^[43] Mast cells, often NF1-heterozygous, infiltrate the lesions and secrete factors that enhance Schwann cell proliferation and migration, while fibroblasts contribute to extracellular matrix production, creating a permissive niche for tumorigenesis.^[44] This interdependent cellular network underscores how initial genetic alterations in Schwann cells propagate through microenvironmental cues to form mature neurofibromas.^[37]

Clinical Features

Symptoms and Signs

Neurofibromas often present as asymptomatic lesions, particularly in the case of cutaneous types, which are common and typically do not cause discomfort unless irritated.^[1] When symptoms occur, they may include pain, tingling, or itching, especially if the tumor compresses nearby nerves or is located in deeper tissues such as subcutaneous or plexiform variants.^[3]^[45] Numbness or weakness can also arise from nerve involvement in these deeper neurofibromas.^[1] On physical examination, neurofibromas appear as soft, movable, rubbery lumps or bumps on or under the skin, often skin-colored, pink, or tan in hue.^[1]^[45] In individuals with neurofibromatosis type 1 (NF1), café-au-lait spots frequently co-occur as additional skin findings alongside the tumors.^[46] Plexiform neurofibromas may lead to functional deficits such as muscle weakness or skeletal deformities like scoliosis due to their expansive growth along nerve sheaths.^[3] These tumors generally exhibit slow growth over time, with cutaneous neurofibromas often increasing in number and size gradually during adulthood.^[47] The visible and sometimes disfiguring nature of neurofibromas, particularly when numerous or located on the face, can result in significant psychological impacts, including elevated levels of anxiety, depression, and reduced self-esteem.^[48]^[49]

Associated Complications

Neurofibromas, particularly in neurofibromatosis type 1 (NF1), can lead to various neurological complications due to their potential to compress or infiltrate nerves and surrounding structures. Cutaneous and subcutaneous neurofibromas may cause localized pain, paresthesia, or motor deficits through direct nerve involvement, while plexiform neurofibromas, present in 30-50% of NF1 patients on MRI, often result in more severe compression leading to chronic pain or functional impairment.^[18] Spinal involvement from neurofibromas or associated dysplasia contributes to scoliosis, affecting 10-30% of individuals with NF1 and potentially causing progressive deformity or respiratory compromise if untreated.^[50] Cosmetic and psychosocial complications arise prominently from visible or disfiguring neurofibromas, impacting quality of life in many NF1 patients. Cutaneous neurofibromas, which develop in nearly all adults with NF1, can lead to significant aesthetic concerns and social stigma, contributing to reduced self-esteem and emotional distress.^[18] Psychosocial burdens include elevated rates of anxiety and depression, with studies reporting symptoms in up to 55% of patients, often linked to visible tumors and chronic disease management.^[51] Systemic complications from neurofibromas are less common but can be serious, especially with large plexiform variants. These tumors may rarely cause airway obstruction, necessitating urgent intervention in affected individuals.^[52] Vascular abnormalities in NF1, such as arterial stenoses or aneurysms, occur in a subset of cases and can lead to hypertension (in ≥15-20% of individuals), stroke, or other ischemic events.^[18] A key concern is the malignant transformation risk, with neurofibromas in NF1 carrying an 8-13% lifetime probability of progressing to malignant peripheral nerve sheath tumors (MPNST). This risk is substantially higher for plexiform neurofibromas, where transformation rates can reach 10-15%, underscoring the need for vigilant monitoring.^[18]

Diagnosis

Clinical Assessment

Clinical assessment of suspected neurofibromas begins with a detailed medical history to identify risk factors and clinical patterns associated with neurofibromatosis type 1 (NF1), a genetic disorder linked to these tumors. Patients are queried about family history of NF1, as approximately 50% of NF1 cases have an affected first-degree relative, while the remainder arise from de novo mutations. The age of onset is typically noted, with cutaneous neurofibromas often appearing in adolescence or early adulthood, though plexiform variants may be present at birth or early childhood. Changes in lesion growth, such as rapid enlargement during puberty, pregnancy, or trauma, are documented, alongside symptoms including localized pain, itching, or functional impairments like reduced mobility if tumors affect nerves or joints. The physical examination focuses on systematic evaluation of skin and subcutaneous tissues to detect and characterize neurofibromas while identifying other NF1 stigmata. Cutaneous neurofibromas, appearing as soft, dome-shaped nodules often pedunculated and pigmented, are counted across the body, with emphasis on areas like the trunk and extremities where they cluster. Deeper subcutaneous or nodular neurofibromas are assessed through palpation, noting their firm, mobile nature and potential tenderness, particularly along nerve distributions. Concurrent NF1 features are evaluated, including the presence of six or more café-au-lait macules greater than 5 mm in prepubertal individuals (or 15 mm postpubertal), axillary or inguinal freckling, and Lisch nodules or choroidal abnormalities via slit-lamp examination or fundoscopy if indicated. Optic pathway gliomas are assessed via neuroimaging if clinically suspected.^[53] Diagnosis of NF1, relevant for cases with multiple neurofibromas or other suggestive features, is based on the revised 2021 international consensus criteria. These criteria allow for diagnosis if there is a heterozygous pathogenic NF1 variant (germline or mosaic) with a variant allele fraction of at least 10% in normal tissue, or two or more of the following cardinal clinical features: six or more café-au-lait macules of specified size; freckling in the axillary or inguinal regions; two or more neurofibromas of any type or one plexiform neurofibroma; optic pathway glioma; two or more Lisch nodules or two or more choroidal abnormalities; a distinctive osseous lesion such as sphenoid dysplasia or tibial pseudarthrosis; or a first-degree relative with NF1. This updated framework, building on the 1987 NIH criteria, integrates molecular genetic testing, which is recommended for confirmation in atypical or young cases, enabling earlier and more precise diagnosis without relying solely on clinical signs.^[53] For individuals diagnosed with NF1, routine clinical screening is recommended to monitor neurofibroma development and progression, including annual comprehensive physical examinations starting at age 10 to track lesion burden and detect complications early. If clinical assessment suggests deeper involvement, imaging may be considered for further evaluation.

Imaging and Histopathology

Magnetic resonance imaging (MRI) is the preferred modality for evaluating neurofibromas due to its superior soft tissue contrast and ability to assess tumor extent and characteristics. On T2-weighted images, neurofibromas typically appear hyperintense, often exhibiting the characteristic "target sign," which consists of a central area of low signal intensity surrounded by a peripheral hyperintense rim, attributed to a fibrocollagenous core and myxomatous tissue, respectively.^[54]^[55] This sign is particularly useful in differentiating benign neurofibromas from malignant peripheral nerve sheath tumors, where it is less commonly observed.^[56] For superficial lesions, ultrasound serves as an initial imaging tool, revealing well-defined, hypoechoic masses with possible posterior acoustic enhancement, aiding in the assessment of cutaneous and subcutaneous neurofibromas without radiation exposure.^[57] Computed tomography (CT) is employed when bony involvement is suspected, such as in neurofibromatosis type 1 (NF1)-associated skeletal dysplasia, demonstrating expansile lesions or erosions along bone margins. In NF1 patients, whole-body MRI is recommended for surveillance to detect and monitor multiple neurofibromas, including plexiform variants, providing a non-ionizing method to quantify tumor burden and identify asymptomatic lesions.^[18]^[58] Histopathological examination via biopsy reveals neurofibromas as unencapsulated tumors composed of bland spindle cells with thin, wavy nuclei embedded in a loose, myxoid to collagenous matrix, exhibiting low mitotic activity and minimal atypia. Immunohistochemical staining shows positivity for S100 protein in Schwann cells, with scattered CD34-positive fibroblasts and mast cells, confirming neural origin. Unlike schwannomas, which lack entrapped axons and show more organized Verocay bodies, neurofibromas incorporate residual nerve fibers within the lesion, contributing to their infiltrative growth pattern.^[5]^[2]^[59] Differential diagnosis includes lipoma, which presents as a fatty mass on imaging without neural features, and sarcoma, particularly malignant peripheral nerve sheath tumors in NF1, characterized by rapid growth, heterogeneity, and invasion on MRI. Genetic testing for NF1 mutations supports confirmation in ambiguous cases meeting clinical criteria.^[60]^[18] Biopsy is reserved for lesions with clinical suspicion of malignancy, such as rapid enlargement, pain, or neurological deficits, and is generally avoided for typical cutaneous neurofibromas in established NF1 to prevent unnecessary scarring and complications.^[61]^[62]

Treatment

Surgical Interventions

Surgical interventions are a primary treatment modality for neurofibromas, particularly when tumors cause symptoms or functional impairment, though they are not routinely performed for asymptomatic lesions. Indications for surgery include symptomatic relief from pain, neurological deficits, or compression of vital structures, as well as cosmetic concerns for visible cutaneous tumors. In neurofibromatosis type 1 (NF1), where neurofibromas are most common, surgical decisions weigh the benefits against risks of nerve damage and tumor regrowth.^[63]^[28] For cutaneous and subcutaneous neurofibromas, which are often superficial and localized, excision is the standard technique and can typically be performed as an outpatient procedure under local anesthesia. Simple elliptical excision with primary closure is suitable for larger lesions (>4 cm) or those in sensitive areas, yielding minimal scarring and high patient satisfaction. For multiple small lesions (<2 cm), ablative methods such as CO2 laser vaporization or shave biopsy with forceps extraction are effective, allowing treatment of numerous tumors in a single session and providing histological confirmation when needed. These approaches prioritize cosmesis and symptom relief, with low morbidity reported in uncomplicated cases.^[64]^[65] Plexiform neurofibromas, which are more diffuse and intertwined with nerves, often require partial or debulking resection to preserve neurological function rather than complete removal, which is achievable in only about 15% of cases. Techniques involve careful microsurgical dissection tailored to the tumor's location, such as orbital or paraspinal approaches, and may necessitate staged procedures for large or extensive tumors to minimize risks. Challenges include significant intraoperative bleeding, potential permanent nerve deficits (occurring in 5-18% of patients), and high recurrence rates of 20-50% following incomplete resection, particularly in pediatric patients or head/neck locations.^[28]^[66]^[67] Outcomes for dermal neurofibromas are generally favorable, with low complication rates and effective symptom resolution. In selected plexiform cases, surgery achieves functional improvement in approximately 70% of patients, including resolution of pain and motor deficits, though rehabilitation is often required postoperatively to restore mobility and prevent stiffness. Overall, while surgery reduces tumor burden and enhances quality of life, multidisciplinary planning is essential to manage recurrence risks and long-term sequelae.^[66]^[68]

Pharmacological Therapies

Pharmacological therapies for neurofibromas primarily target plexiform neurofibromas associated with neurofibromatosis type 1 (NF1), focusing on inhibitors of dysregulated signaling pathways such as the RAS/MEK/ERK cascade.^[69]^[70] Selumetinib and mirdametinib, selective MEK1/2 inhibitors, are FDA-approved targeted therapies for this indication, blocking the hyperactive RAS pathway downstream of NF1 gene mutations to inhibit tumor cell proliferation.^[69]^[71] Selumetinib was initially approved in April 2020 for children aged 2 years and older with symptomatic, inoperable plexiform neurofibromas, with its indication expanded in September 2025 to include patients as young as 1 year old, based on pharmacokinetic, safety, and efficacy data from clinical trials. Mirdametinib was approved in February 2025 for adult and pediatric patients aged 2 years and older with NF1 who have symptomatic, inoperable plexiform neurofibromas.^[69]^[70]^[71] Clinical trials have demonstrated that selumetinib reduces plexiform neurofibroma volume by a median of approximately 27%, with response rates ranging from 20% to 70% depending on the study population and duration, typically assessed via MRI after 12-16 cycles of treatment.^[72]^[73] These reductions are often accompanied by improvements in pain, function, and quality of life, though complete tumor regression is rare.^[72]^[74] For mirdametinib, phase 3 trials (ReNeu) showed a 51% objective response rate (confirmed partial response) compared to 6% with placebo in adults and children aged 2 years and older, with median tumor volume reduction of approximately 28% in responders.^[71]^[75] Other MEK inhibitors, such as trametinib, are under investigation in ongoing phase II trials for similar NF1-associated plexiform neurofibromas, showing partial response rates of up to 47% in adults and manageable safety profiles in pediatric cohorts.^[76]^[77]^[78] In select cases, mTOR inhibitors like everolimus have been explored for NF1-related lesions, with systematic reviews indicating partial reductions in tumor size in a subset of patients, though evidence is more established for associated optic pathway gliomas rather than plexiform neurofibromas alone.^[79]^[80]^[81] These therapies are indicated primarily for symptomatic, inoperable plexiform neurofibromas causing pain, disfigurement, or functional impairment, but they are ineffective for localized cutaneous neurofibromas and are not routinely used for asymptomatic lesions.^[69]^[68] Common side effects include rash, gastrointestinal upset (such as diarrhea, vomiting, and abdominal pain), and fatigue, with most being mild to moderate and manageable through dose adjustments.^[82]^[83] Ophthalmologic monitoring is required due to risks of retinopathy or glaucoma, and treatment response is evaluated periodically using MRI to measure tumor volume changes.^[69]^[68]

Other Modalities

Radiation therapy is rarely utilized in the management of neurofibromas, primarily due to the heightened risk of secondary malignancies in patients with neurofibromatosis type 1 (NF1).^[84]^[85] This risk is estimated at 0.5–3% after 30 years for radiation-induced tumors following treatment of benign conditions.^[86] It may be considered palliatively for inoperable plexiform neurofibromas causing severe pain or functional impairment, where stereotactic radiosurgery provides precise targeting to limit exposure to adjacent healthy tissue.^[87]^[88] However, neurofibromas often exhibit poor clinical response to radiation owing to their infiltrative nature.^[89] Supportive care addresses symptom relief and quality of life, including pain management with nonsteroidal anti-inflammatory drugs (NSAIDs) for inflammatory components and gabapentin for neuropathic pain associated with nerve compression.^[90]^[27] Physical therapy helps mitigate functional deficits by enhancing strength, balance, coordination, and mobility in affected areas.^[68]^[91] Cosmetic camouflage makeup offers a non-invasive option to conceal visible cutaneous lesions, improving psychosocial outcomes for patients with disfiguring manifestations.^[92]^[93] Regular monitoring is vital for early detection of progression, typically involving serial magnetic resonance imaging (MRI) to assess plexiform neurofibroma growth and involvement of nearby structures.^[68]^[94] Multidisciplinary NF1 clinics provide coordinated care from specialists in neurology, oncology, and rehabilitation to optimize long-term surveillance and intervention planning.^[95]^[96] Historically, cryotherapy was applied to small cutaneous neurofibromas as a minimally invasive alternative to excision, though it has become less favored due to risks of significant pain, blistering, and incomplete resolution.^[97] Contemporary evaluations continue to explore its role, but it is not routinely recommended over established supportive measures.^[98]

Prognosis

Benign vs Malignant Transformation

Neurofibromas are predominantly benign tumors that typically remain stable throughout an individual's lifetime. Solitary neurofibromas, which occur sporadically outside of neurofibromatosis type 1 (NF1), exhibit an extremely low risk of malignant transformation, with reported rates well below 1%.^[2] In contrast, plexiform neurofibromas in patients with NF1 carry a higher lifetime risk of progression to malignancy, estimated at 8-13%.^[99] Malignant transformation of neurofibromas most commonly results in malignant peripheral nerve sheath tumors (MPNSTs), particularly in the context of NF1, where these arise from preexisting plexiform neurofibromas through the accumulation of additional genetic alterations beyond the initial NF1 mutation. Key molecular events include loss-of-function mutations in tumor suppressor genes such as TP53, which contribute to tumor progression and are detected in approximately 11% of MPNST cases, often correlating with higher tumor grades.^[100] Clinical indicators suggestive of this transformation include rapid enlargement of the lesion, new-onset or worsening pain, and neurological symptoms such as deficits or changes in sensation, which serve as critical red flags prompting urgent evaluation.^[18] Several risk factors elevate the likelihood of malignant transformation in NF1-associated plexiform neurofibromas. Larger tumor burden, including extensive plexiform neurofibromas, is associated with increased risk, as higher overall volume correlates with greater potential for progression. Prior exposure to ionizing radiation, such as from therapeutic interventions, further heightens susceptibility, with MPNSTs occasionally developing years after radiation therapy. The typical age at diagnosis for MPNST in NF1 patients falls between 20 and 40 years, underscoring the need for vigilant monitoring during early adulthood.^[101]^[102]^[103] Detection of malignant transformation relies on advanced imaging to assess metabolic activity and distinguish benign from suspicious lesions. Positron emission tomography-computed tomography (PET-CT) using 18F-fluorodeoxyglucose (FDG) is particularly effective, demonstrating high sensitivity and accuracy in identifying MPNSTs by highlighting hypermetabolic regions indicative of malignancy in NF1 patients.^[104] Once diagnosed, MPNSTs confer a poor prognosis, with 5-year survival rates for NF1-associated cases ranging from 16% to 26%, influenced by factors such as tumor size, location, and metastatic potential.^[105]

Management of Complications

Management of complications in neurofibromatosis type 1 (NF1), which underlies most neurofibromas, emphasizes proactive surveillance to detect and address issues early, thereby mitigating long-term morbidity. Annual comprehensive clinical examinations by a physician experienced in NF1 are recommended to monitor for tumor growth, skeletal abnormalities, neurological deficits, and other manifestations.^[18] For individuals with NF1, whole-body MRI may be considered starting in adulthood to assess plexiform neurofibromas and enable early intervention for rapid growth or symptomatic changes, though the optimal frequency is not established; such imaging can lead to pain, disfigurement, or functional impairment if changes progress undetected.^[106] Early detection through such imaging facilitates timely surgical or supportive measures, preventing progression of complications like nerve compression or vascular issues.^[107] Complication-specific strategies are tailored to common NF1-associated problems. Orthopedic evaluation and intervention, including bracing or spinal fusion for dystrophic scoliosis affecting up to 10% of patients, are crucial to prevent respiratory or mobility limitations.^[108] Chronic pain from neurofibromas, reported in over 40% of adults, warrants referral to specialized pain clinics for multimodal management, such as nerve blocks or physical therapy, to improve daily functioning.^[18] Psychological support is integral, with counseling or cognitive-behavioral therapy addressing disfigurement-related anxiety, learning disabilities, or social stigma, often integrated into educational plans for affected children.^[108] Enhancing quality of life involves multidisciplinary teams comprising geneticists, oncologists, dermatologists, and other specialists to coordinate care across the lifespan.^[18] Patient registries, such as the NF Registry maintained by the Children's Tumor Foundation, support long-term tracking of outcomes and facilitate personalized follow-up by aggregating data on disease progression and interventions.^[109] These approaches, including vigilant monitoring for risks like malignant peripheral nerve sheath tumors (MPNSTs), underscore the need for integrated care.^[106] Outcomes from structured surveillance demonstrate significant benefits, with early detection linked to improved survival rates through prompt management of tumors and decreased overall morbidity via targeted therapies that limit disability.^[110] Multidisciplinary oversight contributes to better management of NF1 complications throughout adulthood.^[107]

Research Directions

Current Studies

Ongoing clinical trials are advancing the understanding of neurofibroma management in neurofibromatosis type 1 (NF1), particularly through phase III evaluations of selumetinib's long-term effects on plexiform neurofibromas (PN). The KOMET trial (NCT04924608), a randomized, double-blind, placebo-controlled phase III study, demonstrated sustained tumor volume reduction in adults with symptomatic, inoperable NF1-PN, with 20% of selumetinib-treated participants achieving a partial response (≥20% volume decrease) by cycle 16, alongside reductions in chronic pain and analgesia use.^[111]^[112] These findings build on earlier pediatric data, confirming selumetinib's efficacy in maintaining volume reductions over extended treatment periods without new safety signals.^[113] The Children's Tumor Foundation supports key natural history studies to track NF1 progression, including a five-year prospective evaluation of cutaneous neurofibromas in individuals with NF1, which has enrolled over 494 participants to assess tumor formation, growth rates, and associated symptoms.^[114] This longitudinal effort, presented at the 2025 NF Conference, provides critical data on disease variability and informs surveillance strategies.^[115] Recent consensus guidelines from 2024 emphasize early initiation of MEK inhibitors like selumetinib in NF1-PN management to optimize outcomes, recommending their use in symptomatic cases based on radiographic and clinical evidence of progression.^[116] In biomarker research, 2024-2025 studies have validated circulating tumor DNA (ctDNA) assays for malignant peripheral nerve sheath tumor (MPNST) detection in NF1, with integrated profiling of single nucleotide variants, copy number alterations, and structural variants achieving high sensitivity for early identification of transformation from benign neurofibromas.^[117]^[118] Additionally, 2025 epidemiological data refine NF1 penetrance estimates to nearly 100%, with 99% of affected individuals manifesting café-au-lait macules by age one, underscoring the disorder's near-complete expressivity.^[18]^[119]

Emerging Therapies

Emerging gene therapy approaches for neurofibroma aim to directly address the underlying NF1 gene mutations by restoring neurofibromin function or editing defective alleles. CRISPR-Cas9-based editing of the NF1 gene has been employed in animal models to disrupt NF1 and study tumorigenesis, revealing potential therapeutic targets such as CRMP2 for pain management in neurofibromatosis type 1 (NF1)-related conditions.^[120] In 2025 preclinical studies, somatic CRISPR-Cas9 mutagenesis in mice demonstrated that NF1 loss combined with CDKN2A or TP53 alterations drives malignant peripheral nerve sheath tumor (MPNST) development, highlighting opportunities for targeted editing to prevent progression from benign neurofibromas.^[121] Similarly, CRISPR-based inactivation of NF1 in induced pluripotent stem cell (iPSC)-derived neural crest cells has recapitulated neurofibroma formation in three-dimensional models, supporting the use of gene editing to correct mutations in Schwann cell precursors.^[122] Adeno-associated virus (AAV) vectors have shown promise in delivering miniaturized NF1 gene constructs to restore neurofibromin expression, with engineered AAV-557 variants achieving high transduction in NF1-deficient tumor cells and suppressing tumor growth in mouse models of plexiform neurofibromas and MPNSTs.^[123] These advancements have paved the way for phase I clinical trials of AAV-based neurofibromin restoration therapies, anticipated to commence in 2025 to evaluate safety in patients with unresectable NF1-associated tumors.^[124] Novel molecular targets are being explored to modulate epigenetic and signaling pathways in neurofibroma pathogenesis, particularly to prevent malignant transformation. Histone deacetylase (HDAC) inhibitors induce autophagy and apoptosis in MPNST cells, offering a mechanism to target epigenetic dysregulation in NF1-driven tumors.^[125] Enhancer of zeste homolog 2 (EZH2) inhibitors, which disrupt polycomb repressive complex 2 (PRC2) activity, have demonstrated antitumor effects by downregulating nuclear transport proteins like KPNB1, reducing proliferation in MPNST models and potentially halting progression from neurofibromas.^[126] Recent genomic analyses confirm frequent PRC2 component mutations (e.g., EED, SUZ12) in MPNSTs across NF1 stages, underscoring EZH2 inhibition as a preventive strategy against epigenetic reordering that promotes oncogenesis.^[127] For resistant plexiform neurofibromas, combination therapies targeting MEK and BRAF kinases address hyperactive RAS signaling, with preclinical data showing tumor shrinkage in murine models when BRAF/CRAF inhibition is paired with MEK blockade.^[128] Clinical exploration of BRAF-MEK combinations in 2025 has highlighted their potential in NF1 contexts where single-agent MEK inhibitors show limited efficacy, though careful patient selection is needed due to contraindications in other BRAF-mutant cancers. In February 2025, the FDA approved mirdametinib, another MEK inhibitor, for adult and pediatric patients (≥2 years) with symptomatic, inoperable NF1-associated plexiform neurofibromas, expanding pharmacological options alongside selumetinib.^[129]^[130] Stem cell-based strategies focus on intervening early in neurofibroma initiation by targeting Schwann cell precursors (SCPs), the likely cells of origin for plexiform neurofibromas. Embryonic SCPs from spinal nerve roots, marked by GAP43 and PLP expression, give rise to NF1-associated tumors when NF1 is lost, providing a window for therapies that restore self-renewal regulation.^[131] Spatiotemporal NF1 inactivation in the Schwann cell lineage during development recapitulates neurofibromagenesis in mouse models, suggesting that stem cell-directed interventions could prevent tumor formation by modulating progenitor proliferation.^[132] Human iPSC-derived models harboring NF1 mutations generate proliferating SCPs that mimic neurofibroma microenvironments, enabling testing of agents that target SCP self-renewal pathways, such as P2RY14-cAMP signaling, to halt initiation without affecting normal glial development.^[133] As of 2025, early data from studies on neuron-NF1 cross-talk have revealed aberrant interactions between NF1-deficient tumors and sensory neurons, suggesting neuroprotective agents as adjunctive therapies. In NF1 neurofibromas, mutant Schwann cells enhance neuronal hyperexcitability via axon-tumor signaling, leading to increased action potentials that promote tumor growth and pain.^[134] Reprogramming this neural-tumor crosstalk with agents that stabilize neuron-glia interactions shows preliminary neuroprotective effects in preclinical models, potentially reducing neurofibroma progression by mitigating inflammatory and proliferative signals from hyperactive axons.^[135] These findings build on RAS pathway dysregulation but emphasize neuron-specific interventions to complement tumor-targeted approaches.^[134]

References

[1]
Neurofibroma - Symptoms and causes - Mayo Clinic
Oct 5, 2024 · A neurofibroma is a type of peripheral nerve tumor that forms a soft bump on or under the skin. The tumor can develop within a major or minor nerve anywhere in ...
[2]
Neurofibroma - StatPearls - NCBI Bookshelf
Neurofibromas are the most prevalent benign peripheral nerve sheath tumor. Often appearing as a soft, skin-colored papule or small subcutaneous nodule, ...
[3]
Neurofibroma: Types, Symptoms & Treatment - Cleveland Clinic
Neurofibromas are benign nerve tumors that are often linked to neurofibromatosis, a genetic disorder. They can show up on your skin or deeper in your body.
[4]
Neurofibroma-general - Pathology Outlines
Apr 11, 2025 · Neurofibroma is a benign peripheral nerve sheath tumor comprised of neuronal and fibrous components; It is composed of Schwann cells, ...
[5]
Neurofibroma - an overview | ScienceDirect Topics
Neurofibroma is a benign peripheral nerve sheath tumor composed of differentiated Schwann cells, perineurial-like cells, fibroblasts, and nerve fibers, with ...
[6]
Neurofibroma | Radiology Reference Article | Radiopaedia.org
Aug 9, 2024 · Neurofibromas are benign (WHO grade 1) peripheral nerve sheath tumors that are usually solitary and sporadic.Plexiform neurofibroma · Diffuse cutaneous neurofibroma · Neurofibromatosis type 1
[7]
Robust surgical approach for cutaneous neurofibroma ... - JCI Insight
Apr 30, 2019 · In the entire study, 83 cNFs were removed and were an average size of 1 cm (SD, 0.35). An average of 6.9 (range: 1–10) cNFs were removed ...
[8]
Diagnostic Pathology of Tumors of Peripheral Nerve - PMC
Feb 16, 2021 · Neurofibroma is another benign tumor composed of neoplastic Schwann cells, but unlike schwannoma, it also contains additional non-neoplastic ...Schwannoma · Neurofibroma · Malignant Peripheral Nerve...
[9]
Malignant peripheral nerve sheath tumor | Radiology Reference Article
Sep 28, 2025 · MPNSTs are forms of peripheral nerve sheath tumors occurring either de novo or arising from pre-existing tumors (eg neurofibromas, schwannomas etc.).
[10]
Neurofibromatosis: chronological history and current issues - PMC
Neurofibromatosis, which was first described in 1882 by Von Recklinghausen, is a genetic disease characterized by a neuroectodermal abnormality.
[11]
Neurofibromatosis Type 1 - DynaMed
Sep 17, 2025 · Epidemiology. Incidence/Prevalence. one of the most common autosomal dominant genetic disorders. 1. ,. 4. reported incidence 1 in 2,500-3,000 ...<|control11|><|separator|>
[12]
Neurofibromatosis Type 1: Background, Epidemiology, Etiology
Feb 26, 2025 · The estimated incidence of neurofibromatosis type 1 (NF1) is 1 in 3000, but the actual frequency may be higher because of less than complete ...
[13]
Pictorial Essay: Imaging of Peripheral Nerve Sheath Tumours
Both benign and malignant PNSTs may be associated with neurofibromatosis. The incidence of PNSTs is approximately 1 per 100,000 individuals per year [2].
[14]
Advanced MR Imaging of Peripheral Nerve Sheath Tumors ...
They may arise either spo- radically (with an incidence of 1 per 100,000 individuals per year; they are most common in individuals 20 to 50 years of age ...
[15]
Target Product Profile for Cutaneous Neurofibromas: Clinical Trials ...
By adulthood, >95% of adults with NF1 have cNFs (Ehara et al., 2018; Huson et al., 1988). The efficacy of current therapies for cNFs, including laser-based ...
[16]
Epidemiology of neurofibromatosis type 1 - PubMed
The prevalence of neurofibromatosis type 1 (NF1) is about 1/3,000. There are no known ethnic groups in which NF1 does not occur or is unusually common.
[17]
Neurofibromatosis 1 - GeneReviews® - NCBI Bookshelf - NIH
Apr 3, 2025 · Individuals with NF1, especially those with plexiform or deep nodular neurofibromas in large numbers or of large size, are at high risk of ...
[18]
Diagnosis, Epidemiology, And Risk Factors Of NF1-PN - AJMC
May 9, 2025 · Globally, NF1 affects approximately 1 in 3000 individuals. Plexiform neurofibromas (PN), a subtype of NF1-associated tumors, occur in up to 50% ...
[19]
Neurofibromatosis type 1 - Orphanet
Epidemiology. Prevalence is reported to be 1/3,000 live births. NF1 is reported in many ethnic groups and affects males and females equally. Clinical ...
[20]
Cutaneous neurofibromas - Neurology.org
Although not life-threatening, cNF have a major effect upon quality of life (QoL) for most patients with NF1 due to their prevalence and disfigurement.
[21]
Cutaneous Findings in Neurofibromatosis Type 1 - PMC - NIH
Jan 26, 2021 · Neurofibroma, Dome—shaped, pink to brown, pedunculated or sessile cutaneous tumors. Plexiform Neurofibroma, Thickened, slightly raised and ...Missing: movable tender<|control11|><|separator|>
[22]
The biology of cutaneous neurofibromas - NIH
The most common tumor in adults with NF1 is cNF, presumably resulting from the biallelic loss of NF1 in the Schwann cell lineage. cNF can vary widely in size ( ...
[23]
An Absence of Cutaneous Neurofibromas Associated with a 3-bp ...
... cutaneous neurofibromas develop only later in childhood or in adulthood. Cutaneous neurofibromas are present in almost all patients with NF1 by age 20 years.
[24]
Cutaneous Neurofibromas and Quality of Life in Adults With ...
Aug 28, 2024 · More than 90% of persons with NF1 develop benign skin tumors called cutaneous neurofibromas (cNFs). cNFs typically arise during puberty ...
[25]
Clinical and genetic aspects of neurofibromatosis 1 - ScienceDirect
Two to 3% of people with NF137 develop a diffuse polyneuropathy that may be associated with multiple nerve root neurofibromas and a high risk of developing ...
[26]
Neurofibromatosis Type 1 - StatPearls - NCBI Bookshelf - NIH
They are usually present during the first two years of life. On palpation, they have a characteristic "bag of worms" sensation. Pain and expansion of the lesion ...Missing: anatomy | Show results with:anatomy
[27]
Management of neurofibromatosis type 1-associated plexiform ...
Plexiform neurofibromas (PN) are histologically benign nerve sheath tumors that occur commonly in individuals with the tumor predisposition syndrome ...
[28]
The Pathoetiology of Neurofibromatosis 1 - ScienceDirect.com
7, 8 The NF1 gene is located on chromosome band 17q11.2, spanning approximately 280 kb of genomic DNA, and is composed of 57 constitutive exons and 4 ...
[29]
NF1 gene: MedlinePlus Genetics
Mar 1, 2007 · The NF1 gene provides instructions for making a protein called neurofibromin. This protein is produced in many types of cells, including nerve cells and ...
[30]
Entry - *613113 - NEUROFIBROMIN 1; NF1 - OMIM - (OMIM.ORG)
The NF1 gene encodes neurofibromin, a cytoplasmic protein that is predominantly expressed in neurons, Schwann cells, oligodendrocytes, and leukocytes.<|control11|><|separator|>
[31]
Clinical and genetic aspects of neurofibromatosis 1 - Nature
Dec 18, 2009 · Two to 3% of people with NF1 develop a diffuse polyneuropathy that may be associated with multiple nerve root neurofibromas and a high risk of ...<|separator|>
[32]
Somatic NF1 Mutation Spectra in a Family With Neurofibromatosis ...
The analysis of somatic NF1 gene mutations in neurofibromas from NF1 patients revealed that each neurofibroma results from an individual second hit mutation, ...
[33]
The NF1 somatic mutational landscape in sporadic human cancers
Jun 21, 2017 · Inactivating NF1 mutations have been detected in approximately 13% of melanomas, alongside mutations in other tumour suppressor genes, including ...
[34]
Germline and somatic NF1 mutations in sporadic and NF1 ...
Nov 10, 2008 · Approximately 27–50% of NF1 patients develop plexiform neurofibromas 2, which are different from cutaneous neurofibromas in terms of size and ...
[35]
PRC2 is recurrently inactivated through EED or SUZ12 loss in ... - NIH
... neurofibroma to a clear loss in MPNST. These data suggest that PRC2 loss is involved in the malignant progression of benign plexiform neurofibroma into MPNST.
[36]
Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor ...
Neurofibromas are complex tumors composed of axonal processes, Schwann cells, fibroblasts, perineurial cells, and mast cells.
[37]
Confirmation of a double-hit model for the NF1 gene in benign ... - NIH
NF1 patients also have an increased incidence of certain malignant tumors that are believed to follow the "two hit" hypothesis, with one allele constitutionally ...
[38]
Cell of origin and microenvironment contribution for NF1-associated ...
In human neurofibromas, Schwann cells with biallelic Nf1 mutations are the most abundant cell type, consistent with the notion that the tumors may initiate in ...
[39]
The therapeutic potential of neurofibromin signaling pathways and ...
Apr 20, 2023 · As neurofibromin regulates the Ras/MAPK pathway, NF1 is included among the RASopathies, a group of developmental disorders caused by germline ...
[40]
Loss of neurofibromin is associated with activation of RAS/MAPK ...
Neurofibromin, the protein product of the NF1 gene, functions as a tumor suppressor, largely by inhibiting Ras activity.
[41]
Combined Targeting of AKT and mTOR Inhibits Proliferation of ... - NIH
Feb 24, 2020 · Persistent signalling via the PI3K/AKT/mTOR pathway is a major driver of malignancy in NF1-associated malignant peripheral nerve sheath tumours ...
[42]
Mast cells and the neurofibroma microenvironment - PMC - NIH
Patients with NF1 have cutaneous, diffuse, and plexiform neurofibromas, tumors comprised primarily of Schwann cells, blood vessels, fibroblasts, and mast cells.
[43]
Nf1-Dependent Tumors Require a Microenvironment Containing Nf1+
Interactions between tumorigenic cells and their surrounding microenvironment are critical for tumor progression yet remain incompletely understood.
[44]
Neurofibroma | Johns Hopkins Medicine
Neurofibromas are benign (noncancerous) tumors that grow on nerves in the body. They consist of an overgrowth of nerve tissue along with blood vessels.Missing: dome- shaped pedunculated movable
[45]
Neurofibromatosis | National Institute of Neurological Disorders and ...
Feb 13, 2025 · Neurofibromatosis (NF) refers to a group of genetic conditions involving the development of tumors that may affect the brain, spinal cord, and the nerves that ...
[46]
Cutaneous neurofibromas in the genomics era: current ... - Nature
Apr 26, 2018 · Their diverse composition is similar to that of the nerve sheath, consisting of Schwann cells, perineural cells, fibroblasts and a collagenous ...
[47]
Emotional functioning of patients with neurofibromatosis tumor ... - NIH
Aug 9, 2012 · Patients with neurofibromatosis reported significantly more symptoms of depression and anxiety, higher levels of perceived stress, and lower levels of self- ...
[48]
Recommendations for Assessing Appearance Concerns Related to ...
Among the most burdensome features of NF1-associated neurofibromas are their disfiguring appearance and negative impact on psychological well-being.
[49]
Current Aspects on the Pathophysiology of Bone Metabolic Defects ...
Jan 15, 2022 · Scoliosis is the most common skeletal problem, affecting 10–30% of NF1 patients. Although the pathophysiology of spinal deformities has not been ...
[50]
The impact of cutaneous neurofibromas on quality of life and mental ...
This study provides insights into the factors contributing to impaired QoL, anxiety, and mood in NF1 patients with cutaneous neurofibromas.
[51]
Neurofibromatosis type 1 - Symptoms and causes - Mayo Clinic
Sep 10, 2024 · This genetic condition causes tumors on nerve tissue. Surgery and other therapies can manage symptoms.
[52]
Neurofibroma | Radiology Reference Article | Radiopaedia.org
Aug 9, 2024 · T1: hypointense · T2. hyperintense. target sign. a hyperintense rim and central area of a low signal may be seen. this is thought to be due to a ...Plexiform neurofibroma · Diffuse cutaneous neurofibroma · Neurofibromatosis type 1
[53]
Teaching NeuroImages: MRI “target sign” and neurofibromatosis ...
Feb 27, 2012 · Target sign in plexiform neurofibroma is due to central fibrocollagenous core (T2-hypointense) surrounded by myxomatous tissue (T2-hyperintense) ...
[54]
MR imaging differentiation of benign and malignant peripheral nerve ...
The target sign on T2-weighted MR imaging is helpful in differentiating neurofibromas from malignant peripheral nerve sheath tumors.
[55]
Superficial Neurofibroma: A Lesion with Unique MRI Characteristics ...
Acharacteristic feature of neurofibromatosis type 1 (NF1) is the occurrence of peripheral nerve sheath tumors, neurofibromas, which are the most common cause of ...<|control11|><|separator|>
[56]
Whole-body MRI evaluation in neurofibromatosis type 1 patients ...
Jan 29, 2022 · The overview of clinical and radiological findings evaluated by whole-body magnetic resonance imaging (WBMRI) in NF1 patients < 3 years old ...
[57]
Neurofibroma - an overview | ScienceDirect Topics
Histologic examination reveals spindle cells with thin, often wavy nuclei that stain positive for S100.72 Treatment of asymptomatic neurofibromas is often ...
[58]
Neurofibroma - Pathology - Orthobullets
Jun 22, 2021 · Neurofibroma · 5% of patients with NF, 10-25% lifetime risk · symptoms include painful, enlarging soft tissue mass · associated with loss of ...
[59]
Guidelines for the diagnosis and management of individuals with ...
Furthermore, biopsy of asymptomatic cutaneous neurofibromas should not be undertaken for diagnostic purposes in individuals with clearcut NF1.
[60]
ERN GENTURIS tumour surveillance guidelines for individuals with ...
Jan 13, 2023 · This guideline recommends that adults with NF1 should be assessed clinically, at least once every three years (Table 1, Table 2). Every visit ...
[61]
Neurofibroma - Diagnosis and treatment - Mayo Clinic
Oct 5, 2024 · Learn about this type of peripheral nerve tumor that forms a soft bump on or under the skin. It can appear anywhere in the body.Missing: definition | Show results with:definition
[62]
Management of cutaneous neurofibroma: current therapy and future ...
Surgical and destructive removal is the mainstay and golden standard of therapy for cNFs. Destructive modalities including CO2 lasers, electrodessications, and ...Missing: indications | Show results with:indications
[63]
Robust surgical approach for cutaneous neurofibroma in ... - NIH
A simple surgical approach for management of cutaneous neurofibromas in NF1 individuals with high clinical efficacy and patient satisfaction is described.Missing: interventions indications challenges
[64]
Surgical management of peripheral nerve sheath tumours in ...
Surgery is safe and effective for (neurofibromatosis associated) peripheral nerve sheath tumours in the paediatric population; however, management needs a ...
[65]
Surgical Treatment and Complications of Deep-Seated Nodular ...
Sep 26, 2022 · Although surgical treatment is indicated for symptomatic PN, its complete removal is frequently challenging due to significant risks of bleeding ...
[66]
Plexiform neurofibroma - Diagnosis and treatment - Mayo Clinic
Aug 19, 2025 · Explore how plexiform neurofibromas are diagnosed and treated using advanced imaging, genetic testing, and a range of medical and surgical ...Diagnosis · Treatment · Preparing For Your...Missing: definition | Show results with:definition
[67]
FDA approves selumetinib for pediatric patients 1 year of age and ...
Sep 10, 2025 · FDA approves selumetinib for pediatric patients 1 year of age and older with neurofibromatosis type 1 with symptomatic, inoperable plexiform ...
[68]
FDA Approval Summary: Selumetinib for Plexiform Neurofibroma
Aug 1, 2021 · On April 10, 2020, the FDA approved selumetinib (KOSELUGO, AstraZeneca) for the treatment of pediatric patients 2 years of age and older with neurofibromatosis ...
[69]
Selumetinib Shrinks Tumors in Children with NF1 - NCI
Jun 8, 2018 · In the current trial, the median change in plexiform neurofibromas volume from baseline was -27% (the range was from -50.6% to 2.2%), the ...
[70]
Selumetinib in Adult Neurofibromatosis 1 with Plexiform Neurofibroma
Jul 13, 2025 · Interim results for the KOMET study are promising, with an ORR of 20% and a 33.9% reduction in tumor volume in participants who completed 16 ...
[71]
MEK inhibitor selumetinib reduces spinal neurofibroma burden in ...
Aug 8, 2020 · The MEK inhibitor selumetinib shrinks the majority of plexiform neurofibromas (PNs) in patients with NF1. We assessed the effect of selumetinib on SNF.Abstract · Patients And Methods · Results
[72]
Trametinib in Adults with Neurofibromatosis Type 1‐Related ...
Aug 22, 2025 · In this phase 2 trial with trametinib, we found a partial response rate of 47% at cycle 12 in adults with NF1-related symptomatic PNs and the ...
[73]
Treatment of NF1-related Plexiform Neurofibroma With Trametinib
A pediatric clinical trial that investigates the potential use of the drug trametinib (Mekinist®) as treatment for symptomatic or likely to become symptomatic ...
[74]
Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)
Conclusions: Trametinib demonstrated a manageable safety profile in pediatric pts with NF-1–associated PN. Using volumetric criteria for response determination, ...
[75]
Everolimus Effect on NF1 Lesions: Systematic Review & Meta Analysis
Sep 6, 2024 · While everolimus shows promise in reducing lesion size in a subset of NF1 patients, the study cannot draw conclusive results due to limitations in the included ...
[76]
A phase II study of continuous oral mTOR inhibitor everolimus for ...
Background: Activation of the mammalian target of rapamycin (mTOR) pathway is observed in neurofibromatosis type 1 (NF1) associated low-grade gliomas (LGGs), ...
[77]
phase II study: oral mTOR inhibitor for NF1 glioma
Oral everolimus demonstrated activity as a single agent for radiographic progressive NF1 LGGs after failure of standard upfront chemotherapy with a favorable ...Abstract · Materials and Methods · Results · Discussion
[78]
Selumetinib side effects in children treated for plexiform neurofibromas
Feb 6, 2021 · The drug's most common side effects, which usually are mild or moderate, include gastrointestinal symptoms (diarrhea, abdominal pain), ...
[79]
Selumetinib: MedlinePlus Drug Information
May 15, 2020 · Selumetinib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: · vomiting · constipation · stomach ...Missing: Pharmacological | Show results with:Pharmacological
[80]
Subsequent Neoplasms After a Primary Tumor in Individuals With ...
Sep 18, 2019 · The risk of SNs was 2.8-fold higher among those treated with radiation when compared with those not exposed to radiation (P = .01; Table 5).
[81]
Risks of radiation therapy in patients with neurofibromatosis - PubMed
Risks of radiation therapy in patients with neurofibromatosis. Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):632. doi: 10.1016/j.ijrobp.2009.03.076.
[82]
Malignant transformation and new primary tumours after therapeutic ...
Overall, these studies indicate that the risk of radiation induced tumours after radiotherapy for benign disease is 0.5–3% after 30 years. The lifetime risk of ...
[83]
Radiotherapy and radiosurgery for benign neurofibromas - PubMed
The purpose of this study was to evaluate the efficacy of radiotherapy (RT) and stereotactic radiosurgery (SRS) for neurofibromas.
[84]
Radiosurgical treatment of ulnar plexiform neurofibroma in a ...
Jan 11, 2013 · This is an interesting case report on a successful radiosurgical treatment for a recurrent neurofibroma of the extremities infiltrating the skin ...
[85]
Long-term outcomes of radiotherapy for inoperable benign soft ... - NIH
Neurofibromas treated with radiotherapy tend to be highly symptomatic and show poor clinical response, partly due to their infiltrative nature leading to ...
[86]
From genes to therapy: navigating the complex landscape of ...
Aug 5, 2025 · Pain management strategies include the use of nonsteroidal anti-inflammatory drugs (NSAIDs), opioids for severe pain, and adjuvant therapies ...Medical Management · Healthcare System And Policy... · Research And Future...
[87]
What To Know About Managing Plexiform Neurofibroma Symptoms
Feb 4, 2025 · Physical therapy and occupational therapy can help you address any challenges that your tumors create. And if you have tumors removed, they can ...
[88]
Neurofibromatosis Type 1 Treatment - News-Medical
Children who are finding them particularly distressing may benefit from camouflage make up to mask the lesions. Treatment of neurofibromas - Neurofibromas ...Missing: cosmetic | Show results with:cosmetic
[89]
Cosmetic camouflage improves quality of life among patients with ...
This study systematically reviewed the impact of cosmetic camouflage use on different psychosocial outcomes in patients with disfiguring skin disorders.
[90]
Imaging Evaluation of Plexiform Neurofibromas in ... - PubMed Central
To assess imaging utilization practices across clinical specialists in neurofibromatosis type 1 (NF1) for the evaluation of symptomatic and asymptomatic ...
[91]
[PDF] PLEXIFORM NEUROFIBROMAS | Children's Tumor Foundation
Unlike cutaneous neurofibromas that typically grow as small nodules, plexiform neurofibromas are often larger, diffuse growths with less well-defined borders. ...Missing: average | Show results with:average
[92]
Neurofibromatosis Multidisciplinary Clinic | Atrium Health Wake ...
We have experts specifically trained in the management of cutaneous neurofibromas, plexiform neurofibromas, and other symptoms of neurofibromatosis.
[93]
Cryotherapy as a Non-surgical Treatment for Palatal Solitary ... - NIH
Apr 6, 2024 · However, for patients who are averse to surgery, cryotherapy has shown success in treating tracheal neurofibromas [4].
[94]
https://pmc.ncbi.nlm.nih.gov/articles/PMC8594007/
[95]
From benign neurofibromas to malignant peripheral nerve sheath ...
Apr 2, 2025 · Somatic mutations of PRC2 complex genes including SUZ12 and EED are found in 70% of NF1-associated, 90% of sporadic and radiotherapy ...<|control11|><|separator|>
[96]
TP53 Mutation Analysis of Malignant Peripheral Nerve Sheath Tumors
Abstract. Mutations in TP53 underlie the development of malignant peripheral nerve sheath tumors (MPNSTs) in animal models, but there is controversy regard.
[97]
Growth dynamics of plexiform neurofibromas: a retrospective cohort ...
Oct 4, 2012 · Higher internal tumour burden appears to be a risk factor for the development of MPNST, and rapid increase in size, the development of ...Missing: cm² | Show results with:cm²
[98]
Diagnosis and management of malignant peripheral nerve sheath ...
The main risk factors for the development of MPNST are existing benign plexiform neurofibromas (PNs),2 prior radiation treatment,3 and large germline mutations ...
[99]
Malignant Peripheral Nerve Sheath Tumors - Rein in Sarcoma
The median age of patients with NF1 who develop malignant peripheral nerve sheath tumors (MPNST) is between 20 – 40 years, versus a median age of 30 – 60 years ...
[100]
18F-FDG PET/CT Qualitative and Quantitative Evaluation in ...
Mar 1, 2015 · 18 F-FDG PET/CT has shown increased accuracy, compared with morphologic imaging, in differentiating malignant peripheral nerve sheath tumors (MPNSTs) from ...
[101]
Six at Sixty. Malignant peripheral nerve sheath tumours in NF1
A study of 1475 patients in North America found 34 new cases of MPNST over a 20-year period, equating to an annual risk of 1.3–6.8 per 1000 during the first to ...
[102]
Care of adults with neurofibromatosis type 1: a clinical practice ...
The optimal use, timing, and utility of screening with whole-body MRI are not known. RECOMMENDATIONS. •. Consider referral to specialized high-volume centers ...Missing: bony | Show results with:bony
[103]
Lifelong Management of Neurofibromatosis 1 Patients - PMC
Beyond oncological risks, NF1 is frequently associated with cognitive and behavioral impairments, including learning disabilities, attention-deficit ...Cancer Predisposition In Nf1 · Fig. 1 · Cognitive And Behavioral...<|control11|><|separator|>
[104]
Health Supervision for Children With Neurofibromatosis Type 1
May 1, 2019 · Its population prevalence is approximately 1 in 3000. The condition is usually recognized in early childhood, when pigmentary manifestations ...
[105]
NF Registry - Children's Tumor Foundation
The NF Registry is a secure, patient-driven website that allows people living with any form of NF (NF1, NF2-SWN, or schwannomatosis) to take an active role in ...
[106]
Close Follow-Up of Patients with Neurofibromatosis Type 1 Reduces ...
Apr 12, 2025 · Early detection of tumours is recommended to minimize tumour-related morbidity and mortality. With this study, we aimed to test whether ...
[107]
Efficacy and safety of selumetinib in adults with neurofibromatosis ...
Jun 2, 2025 · The observations of reduction in tumour volume by cycle 16, reduction in chronic and spike pain, reduction in analgesia, and decrease in ...
[108]
Drug shrinks nerve tumors in adults with neurofibromatosis type 1 in ...
Jan 6, 2025 · In total, 64% of participants experienced a partial response to the therapy, meaning their tumors shrank by 20% or more in volume. The effect ...
[109]
Selumetinib for plexiform neurofibroma: advances and ongoing ...
Oct 3, 2024 · Recently, in Neuro-Oncology, Lee et al reported notable findings from a phase II trial, confirming that 98.9% experienced tumor volume reduction ...
[110]
Natural History Study of Cutaneous Neurofibromas in People with ...
This important project is evaluating how skin neurofibromas form and change over time in people with NF1 over the course of five years.Missing: studies | Show results with:studies
[111]
[PDF] 2025 NF CONFERENCE - Children's Tumor Foundation
Jun 24, 2025 · Neurofibroma Natural History Study in 494 People with NF1. Mandi ... Studies of MEK inhibitors in other NF1 tumors are currently ongoing.
[112]
Consensus recommendations on management of selumetinib ...
Apr 27, 2024 · Selumetinib is the first approved treatment for pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN)<|separator|>
[113]
Single-cell tumor microenvironment profiling informs a circulating ...
Jun 18, 2025 · We built a single-cell dataset of 55 NF1-associated PN, AN, and MPNST to define cellular changes in neurofibroma at-risk of malignant transformation.
[114]
(PDF) Integrated Multiclass Driver ctDNA Profiling Enables MPNST ...
Oct 3, 2025 · We developed and cross‑validated an integrated circulating tumor DNA assay incorporating SNVs, indels, CNAs, and SVs to distinguish ...
[115]
Neurofibromatosis type 1 (NF1): A Hungarian study - AKJournals
Oct 16, 2025 · By 1 year of age, 99% of NF1 patients exhibit six or more CALMs ... Genetic testing for NF1 has a sensitivity of 95%, offering high ...
[116]
CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a ...
CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.
[117]
Somatic CRISPR tumorigenesis and multiomic analysis reveal a ...
Aug 13, 2025 · Loss of CDKN2A or P53 following NF1 disruption is a key event in MPNST development. Here, we used CRISPR-Cas9 somatic tumorigenesis in mice to ...
[118]
[PDF] iPSC-derived NF1-CDKN2A-PRC2 deficient neural crest cells mimic ...
Aug 15, 2025 · For that, we used an iPSC-derived 3D neurofibroma model previously developed in our lab. 36,37. Using CRISPR-based gene editing, we inactivated.
[119]
Development of an adeno-associated virus vector for gene ... - Nature
Sep 29, 2025 · Neurofibromatosis type 1 (NF1) is a tumor predisposition syndrome caused by alterations in NF1 gene that lead to tumor growth throughout the ...
[120]
Johns Hopkins Team Creates Targeted Gene Therapy Vector for ...
Oct 28, 2025 · In animal models, it significantly slowed growth of NF1 tumors, including MPNST, supporting translation to human studies. This work occurred ...Missing: CRISPR- editing 2024
[121]
novel strategies to treat malignant peripheral nerve sheath tumors
HDACis were found to induce productive autophagy in MPNST cells. Genetic and/or pharmacological autophagy blockade resulted in significant HDACi-induced ...Missing: EZH2 | Show results with:EZH2
[122]
Antitumor effects of pharmacological EZH2 inhibition on malignant ...
Mar 7, 2015 · EZH2 knockdown by RNA interference in MPNST cell lines induces MPNST cell apoptosis in vitro and inhibits MPNST tumor growth in vivo, suggesting ...Missing: prevention | Show results with:prevention
[123]
A Sequencing Overview of Malignant Peripheral Nerve Sheath Tumors
Epigenetic alterations, including DNA methylation, histone modifications, and non-coding RNA regulation, play a critical role in the pathogenesis of MPNSTs, as ...
[124]
Selective inhibition of BRAF and CRAF sensitizes NF1-deficient ...
Sep 29, 2025 · Combining SOS1 and MEK inhibitors in a murine model of plexiform neurofibroma results in tumor shrinkage. J Pharmacol Exp Ther. 2023;385(2): ...
[125]
Exploring Novel Treatment Options for Neurofibromatosis Type 1 ...
Sep 16, 2025 · Recent FDA-approved MEK inhibitors, mirdametinib and selumetinib, have transformed NF1-PN treatment, showing tumor shrinkage and symptomatic ...Current Unmet Needs And Gaps... · Mek Inhibition And Emerging... · The Future Of Nf1-Pn Care
[126]
Cells of Origin in the Embryonic Nerve Roots for NF1-Associated ...
Nov 10, 2014 · We showed that the embryonic GAP43 + PLP + Schwann cell precursors originate from spinal nerve roots are the cells of origin for plexiform neurofibromas.
[127]
Spatiotemporal Loss of NF1 in Schwann Cell Lineage Leads to ...
Patients with NF1 present with a wide range of clinical manifestations, and the tumor with highest prevalence is cutaneous neurofibroma (cNF).Missing: presentation reliable<|control11|><|separator|>
[128]
Humanized neurofibroma model from induced pluripotent stem cells ...
We used a unique series of human induced pluripotent stem cells (hiPSCs) harboring NF1 patient NF1 gene mutations to generate proliferating SCPs.
[129]
Reprogramming neural-tumor crosstalk: emerging therapeutic ...
Oct 30, 2025 · In NF1-deficient neurofibromas, sensory axons extending to NF1-mutant dorsal root ganglion neurons exhibit higher action potential issuance ...
[130]
Schwann cells modulate nociception in neurofibromatosis 1
Jan 23, 2024 · As recent studies have been focused on neuron-glia crosstalk, strategies targeting this interaction have gained traction as potential therapies ...Missing: agents | Show results with:agents